Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
Tokyo-based health tech CureApp’s hypertension therapeutic app became available on September 1 with public health coverage in Japan, President Kota Satake said at a press conference held on the same day. The product, dubbed “CureAPP HT hypertension treatment support app…
To read the full story
Related Article
- Teijin to Copromote CureApp’s Hypertension Therapy App
April 24, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- CureApp Wins Japan Nod for Hypertension Therapeutic App, Eyes 2022 Rollout
April 28, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- Therapeutic App for Hypertension Up for PAFSC Review on March 9
February 24, 2022
- CureApp Files Therapeutic App for Hypertension in Japan, Eyes Launch in 2022
September 6, 2021
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
BUSINESS
- Astellas’ Protein Degrader Setidegrasib Enters PIII in US
April 1, 2026
- Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
- Kyorin Exercises Option for BIODOL’s Pain Drug Candidate
April 1, 2026
- UCB Japan Files Zilbrysq Autoinjector in Japan
April 1, 2026
- Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…